Sentiment Trading

Puma Biotechnology Inc.’s recent partnership with Er-Kim for the distribution of NERLYNX represents a high-risk, high-reward strategy that could potentially propel the company to leadership in the cancer treatment landscape.

Puma Biotechnology is a development-stage biopharmaceutical company working to bring innovative cancer treatments to market through its strategic approach to drug development.